ReviewClinical and translational imaging2016
Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology.
Review in Clinical and translational imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Imaging for Metastasis in Prostate Cancer: A Review of the Literature.Frontiers in oncology · 2020Pooled it
- Trial
- Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer.ESMO open · 2020Trial
- Challenges of Bone Scintigraphy in Assessment of Osseous Metastases in Prostate Cancer: Why it is Time to Reconsider Role ofMolecular imaging and biology · 2026Review
- Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223.EJNMMI reports · 2026Article
- Advancements in Skeletal Tumour Management: Linking Metastatic Biology With Surgical Reconstruction.Cureus · 2026Review
- Salvage radiotherapy with prostate-specific membrane antigen-directed focal boost: A precision approach for recurrent prostate cancer.Journal of the Chinese Medical Association : JCMA · 2025Article
- Review
- Unexplained Cardiac Uptake onAsia Oceania journal of nuclear medicine & biology · 2025Article
- Development of a predictive model for preoperative bone metastasis risk assessment in prostate cancer through integration of semi-quantitative single-photon emission computed tomography/computed tomography indices with peripheral blood biomarkers.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Article
- Development of a predictive model for progression to castration-resistant prostate cancer in patients with high bone tumor burden.American journal of cancer research · 2025Article
- Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.Biomedicines · 2024Review
- Article
- Nomogram-based prognostic model construction for progression to castration-resistant prostate cancer in patients with high tumor burden and osseous metastatic prostate cancer.American journal of cancer research · 2024Article
- IncreasedSkeletal radiology · 2023Article
- Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.Cancers · 2023Review
- Magnetic Resonance Imaging Evaluation of Bone Metastases Treated with Radiotherapy in Palliative Intent: A Multicenter Prospective Study on Clinical and Instrumental Evaluation Assessment Concordance (MARTE Study).Diagnostics (Basel, Switzerland) · 2023Article
- Quantitative [EJNMMI physics · 2022Article
- Value of transrectal contrast-enhanced ultrasound with clinical indicators in the prediction of bone metastasis in prostate cancer.Quantitative imaging in medicine and surgery · 2022Article
- Comparison ofEuropean journal of hybrid imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The bone scan continues to be recommended for both the staging and therapy response assessment of skeletal metastases from prostate cancer. However, it is widely recognised that bone scans have limited sensitivity for disease detection and is both insensitive and non-specific for determining treatment response, at an early enough time point to be clinically useful. We, therefore, review the evolving roles of nuclear medicine and radiology for this application. We have reviewed the published literature reporting recent developments in imaging bone metastases in prostate cancer, and provide a balanced synopsis of the state of the art. The development of single-photon emission computed tomography combined with computed tomography has improved detection sensitivity and specificity but has not yet been shown to lead to improvements in monitoring therapy. A number of bone-specific and tumour-specific tracers for positron emission tomography/computed tomography (PET/CT) are now available for advanced prostate cancer that show promise in both clinical settings. At the same time, the development of whole-body magnetic resonance imaging (WB-MRI) that incorporates diffusion-weighted imaging also offers significant improvements for detection and therapy response assessment. There are emerging data showing comparative SPECT/CT, PET/CT, and WB-MRI test performance for disease detection, but no compelling data on the usefulness of these technologies in response assessment have yet emerged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.